Evidence map›Paper›PMID 42529391›Full record

ArticleJACS Au2026

A Ligand-Triggered Receptor Conformation Enables the Design of Selective Agonists for the Dopamine 3 Receptor (D

Sandra Arroyo-Urea, Antonina L Nazarova, Alexander Knieb, Hawau Abdulsalam, Khorshada Jahan, Ting Du, Song Gao, Amy Hauck Newman, Vsevolod Katritch, Javier García-Nafría and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sandra Arroyo-UreaInstitute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratory of Advanced Microscopy (LMA), University of Zaragoza, Zaragoza 50018, Spain.
Antonina L NazarovaDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, California 90089, United States.
Alexander KniebDepartment of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Hawau AbdulsalamDepartment of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Khorshada JahanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, United States.
Ting DuDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas 77004, United States.
Song GaoDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas 77004, United States.
Amy Hauck NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, United States.ORCID https://orcid.org/0000-0001-9065-4072
Vsevolod KatritchDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, California 90089, United States.ORCID https://orcid.org/0000-0003-3883-4505
Javier García-NafríaInstitute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratory of Advanced Microscopy (LMA), University of Zaragoza, Zaragoza 50018, Spain.
Alessandro BonifaziDepartment of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, Texas 77555, United States.ORCID https://orcid.org/0000-0002-7306-0114

Funding

NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8M
Computational approaches to discover ligands with new chemotypes and functional propertiesR35GM153437 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VSEVOLOD KATRITCH · 2024 to 2026
$899k
Intramural NIH HHS Z01 DA000424NIGMS NIH HHS R35 GM153437
6 · The paper itself

Abstract

While G protein-coupled receptors (GPCRs) represent the largest drug target family, designing subtype-selective molecules is still a challenge, especially to distinguish among closely related subtypes. One of the most challenging cases is the distinction between dopamine D

Indexed as

bitopic moleculesdopamine receptordrug selectivityGPCRsG protein-coupled receptorsligand-triggered receptor conformationstructure-based drug design

Identifiers

PMID42529391
PMCPMC13417268

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.